Skip to main content

Table 2 Patient characteristics and 3-month survival

From: A prospective randomized open-label crossover trial of regional citrate anticoagulation vs. anticoagulation free liver dialysis by the Molecular Adsorbents Recirculating System

Patient

Age

Etiology

Child

MELD

Day 1

Sessions

3m survival

1

52

Alcoholic

B9

22

citrate

4

deceased

2

47

Alcoholic

C13

43

nil

3

deceased

3

32

Alcoholic

C11

26

nil

3

transplanted, alive

4

68

Hepatitis C

C11

34

citrate

2

lost to follow up

5

51

Alcoholic

C10

23

nil

3

alive

6

63

Alcoholic

C10

30

citrate

4

alive

7

65

Graft failure

B9

23

citrate

3

alive

8

50

NASH

C12

36

nil

3

transplanted, alive

9

64

Alcoholic

C13

34

nil

1

deceased

10

54

α1-AT deficiency

C13

50

citrate

1

deceased

  1. α1-AT deficiency, α1-antitrypsin deficiency; MELD, model for end-stage liver disease